Introduction
In settings where HIV is prevalent in heterosexual populations, women have higher than acceptable HIV risk during pregnancy and lactation, with reported pooled cumulative HIV incidence of 3.8 per 100 woman-years (4.7/100 woman-years during pregnancy and 2.9/100 woman-years during lactation period) in one review [ , ] . Elevated risk during these periods in many of these settings is because the general HIV risk is higher than acceptable but may also result from infrequent condom use, unknown partner's HIV status, and biologic changes in women during pregnancy and lactation or changes in their partner's sexual -behavior that increase susceptibility to
Mechanism of action and clinical pharmacology
TDF is a prodrug for tenofovir ( Tenofovir has poor bioavailability, but after oral administration as TDF, it is rapidly converted into tenofovir which is subsequently metabolized intracellularly to tenofovir diphosphate, its active metabolite [ ].
Tenofovir readily crosses into placenta and amniotic fluid but only appears in suboptimal levels in breast milk [ -] . For breastfeeding women taking oral TDF PrEP, breastmilk will exclusively contain tenofovir in an unconjugated form, and because of its poor oral bioavailability, negligible tenofovir concentrations would be expected to be excreted into breastmilk and subsequently available to the infants through breastfeeding. Studies of pregnant women on TDF for treatment of HIV infection have reported tenofovir umbilical cord levels >70-100% compared to maternal plasma concentration indicating high placental transfer [ -] . TDF is classified as US Food 
Safety evaluation
We conducted a review of literature to identify published 
HIV-uninfected women using TDF-based PrEP during breastfeeding
There are 
Corollary information from HIV-infected women using TDF-based HIV treatment and from use of TDF during pregnancy
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